Anavex Life Sciences Corp (AVXL)

[Steady_T]

There is a very specific procedure the FDA has for getting biomarkers accepted as surrogate endpoints. That is, those used in accelerated applications.
If the Ab ratio is not accepted an surrogate endpoint the the trial has to be evaluated on the pre defined endpoint.

The improved Ab ratio will be considered as supporting evidence but not in place of the defined endpoints.